Pharmacokinetic fluvoxamine - Clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient

Pharmacopsychiatry

Volumn 29, Issue 3, 1996, Pages 108-110

  Conus, P ^a   Bondolfi, G ^a   Eap, C B ^a   Macciardi, F ^b   Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; CLORAZEPATE; CYTOCHROME P450 ISOENZYME; DIBENZEPIN; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MOCLOBEMIDE; NORCLOMIPRAMINE; NORTRIMIPRAMINE; PAROXETINE; SERTRALINE; TRIMIPRAMINE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG BLOOD LEVEL; GAS CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; SMOKING;

EID: 0030010301     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979554     Document Type: Article

References (30)

1. Balant-Gorgia, A. E., L. P. Balant, C. Genet, P. Dayer, J. M. Aeschlimann, C. Garrone: Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur. J. Clin. Pharmacol. 31 (1986) 449-455
2. Baumann, P., M. Jonzier-Perey, L. Koeb, A. Kupfer, D. Tinguely, J. Schöpf: Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int. Clin. Psychopharmacol. 1 (1986) 102-112
3. Baumann, P., J. W. Meyer, M. Amey, D. Baettig, C. Bryois, M. Jonzier-Perey, L. Koeb, C. Monney, B. Woggon: Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug Monit. 14 (1992) 1-8
4. Baumann, P., R. Nil, A. Souche, S. Montaldi, D. Baettig, S. Lambert, C. Uehlinger, A. Kasas, M. Amey, M. Jonzier-Perey: A double-blind placebo controlled study of citalopram with and without lithium in the treatment of therapy-resistent depressive patients. A clinical, pharmacokinetic and pharmacogenetic investigation. J. Clin. Psychopharmacol. (in press)
5. Bertilsson, L., A. Åberg-Wistedt, L. L. Gustafsson, C. Nordin: Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther. Drug Monit. 7 (1985) 478-480
6. Bertilsson, L., M.-L. Dahl, F. Sjöqvist, A. Åberg-Wistedt, M. Humble, I. Johansson, E. Lundqvist, M. Ingelman-Sundberg: Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341 (1993) 63
7. Bertschy, G., S. Vandel, B. Vandel, G. Allers, R. Volmat: Fluvoxamine-tricyclic antidepressant interaction - An accidental finding. Eur. J. Clin. Pharmacol. 40 (1991) 119-120
8. Brøsen, K., E. Skjelbo, B. B. Rasmussen, H. E. Poulsen, S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45 (1993) 1211-1214
9. Brøsen, K., L. F. Gram: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 36 (1989) 537-547
10. Chiba, K., A. Saitoh, E. Koyama, M. Tani, M. Hayashi, T. Ishizaki: The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Brit. J. Clin. Pharmacol. 37 (1994) 237-242
11. Cournoyer, G., C. De Montigny, J. Ouellette, R. Langlois, R. Elie, G. Caille, P. Le Morvan: A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J. Clin. Psychopharmacol. 7 (1987) 385-393
12. Gough, A. L., J. S. Miles, N. K. Spurr, J. E. Moss, A. Gaedigk, M. Eichelbaum, C. R. Wolf: Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347 (1990) 773-776
13. Hamilton, M.: Development of a rating scale for primary depressive illness. Brit. J. Soc. Clin. Psychol. 6 (1967) 278-296
14. Härtter, S., H. Wetzel, E. Hammes, C. Hiemke: Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 110 (1993) 302-308
15. Hyttel, J.: Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 6 (1982) 277-295
16. Kasper, S., M. Dötsch, H. Kick, A. Vieira, H.-J. Möller: Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effets. Eur. neuropsychopharmacol. 3 (1993) 13-21
17. Kramer Nielsen, K., K. Brøsen, M. G. J. Hansen, L. F. Gram: Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol. Ther. 55 (1994) 518-527
18. Lahiri, D. K., J. L. Nurnberger Jr.: A rapid non-enzymatic method for the preparation of HMV DNA from blood for RFLP analysis. Nucl. Acids Res. 19 (1991) 5444
19. Lemoine, A., J. C. Gautier, D. Azoulay, L. Kiffel, C. Belloc, F. P. Guengerich, P. Maurel, P. Beaune, J. P. Leroux: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43 (1993) 827-832
20. Meyer, U. A.: The molecular basis of genetic polymorphisms of drug metabolism. J. Pharm. Pharmacol. 46 (suppl. 1) (1994) 409-415
21. Seifritz, E., E. Holsboer-Trachsler, U. Hemmeter, C. B. Eap, P. Baumann: Increased trimipramine plasma levels during fluvoxamine comedication. Eur. Neurophsychopharmacol. 4 (1994) 15-20
22. Skjelbo, E., K. Brøsen, J. Hallas, L. F. Gram: The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49 (1991) 18-23
23. Skjelbo, E., K. Brøsen: Inhibitors of imipramine metabolism by human liver microsomes. Brit. J. Clin. Pharmacol. 34 (1992) 256-261
24. Souche, A., P. Baumann, L. Koeb, P. Thermoz, J. M. Azorin, H. Dufour: Traitement de la dépression par l'association de la clomipramine et de la triiodothyronine (LT3). Encéphale 17 (1991) 37-42
25. Spina, E., G. M. Campo, A. Avenoso, M. A. Pollicino, A. P. Caputi: Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther. Drug. Monit. 14 (1992) 194-196
26. Sternbach, H.: The serotonin syndrome. Amer. J. Psychiatry 148 (1991) 705-713
27. Sutfin, T. A., G. I. Perini, G. Molnar, W. J. Jusko: Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J. Clin. Psychopharmacol. 8 (1988) 48-53
28. Vandel, B., S. Vandel: Facteurs pharmacocinétiques et résistance aux traitements antidépresseurs. Encéphale 12 (1986) 217-222
29. Vandel, S., G. Bertschy, P. Baumann, S. Bouquet, B. Bonin, T. François, D. Sechter, P. Bizouard: Fluovoxamine and fluoxetine: Interactions studies with amitriptpyline, clomipramine, and neuroleptics in phenotyped patients. Pharmacol. Res. 31 (1995) 347-353
30. Wolf, C. R., J. E. Moss, J. S. Miles, A. C. Gough, N. K. Spurr: Detection of debrisoquine hydroxylation phenotypes. Lancet 336 (1990) 1452-1453